33 results about "Mesodermal cell" patented technology

The present invention provides compositions and methods for the production of differentiated mammalian cells. More particularly, the present invention provides cellular differentiation methods employing culturing the cells on a feeder layer or under feeder-free conditions in cell culture and further contacting the cells with an inhibitor of the PI3-kinase pathway for the generation of differentiated mammalian cells from pluripotent mammalian stem cells. Preferably, the differentiated cell is selected from the group consisting of a mesendodermal cell, a mesodermal cell, and an endodermal cell.

The present invention relates generally to the generation of cells of mesodermal lineage. More particularly, the present invention contemplates a method for the preparation of differentiated or partially differentiated mesodermal cells and their use in tissue repair, regeneration and / or augmentation therapy. The identification and generation of the mesodermal cells further provides a source of transcriptome or proteome data to assess the expression profile of genes associated with the maintenance of mesodermal cells as well as their differentiation, proliferation, expansion and / or renewal potential.

The present invention relates to placenta tissue-derived multipotent stem cells and cell therapeutic agents containing the same. More specifically, to a method for producing placenta stem cells having the following characteristics, the method comprising culturing amnion, chorion, decidua or placenta tissue in a medium containing collagenase and bFGF and collecting the cultured cells: (a) showing a positive immunological response to CD29, CD44, CD73, CD90 and CD105, and showing a negative immunological response to CD31, CD34, CD45 and HLA-DR; (b) showing a positive immunological response to Oct4 and SSEA4; (c) growing attached to plastic, showing a round-shaped or spindle-shaped morphology, and forming spheres in an SFM medium so as to be able to be maintained in an undifferentiated state for a long period of time; and (d) having the ability to differentiate into mesoderm-, endoderm- and ectoderm-derived cells. Also the present invention relates to placenta stem cells obtained using the production method. The inventive multipotent stem cells have the ability to differentiate into muscle cells, vascular endothelial cells, osteogenic cells, nerve cells, satellite cells, fat cells, cartilage-forming cells, osteogenic cells, or insuline-secreting pancreatic β-cells, and thus are effective for the treatment of muscular diseases, osteoporosis, osteoarthritis, nervous diseases, diabetes and the like, and are useful for the formation of breast tissue.

Provided is a method of producing a skeletal muscle progenitor cell using a pluripotent stem cell, particularly an iPS cell, the method comprising the step 1) of culturing a pluripotent stem cell under serum-free conditions, and in the presence of Activin A, to allow the cell to differentiate into a PDGFRα-positive mesodermal cell, and the step 2) of culturing the mesodermal cell under serum-free conditions, and in the presence of a Wnt signal inducer, to allow the cell to differentiate into a skeletal muscle progenitor cell. Also provided are a cell population containing a skeletal muscle progenitor cell as obtained by the method, and a skeletal muscle regeneration promoting agent and therapeutic agent for muscular diseases such as muscular dystrophy, the promoting agent or agent comprising the skeletal muscle progenitor cell as an active ingredient.

A tissue structure for enabling comprehensive understanding of gene patterns of mature cells and a method of preparing the tissue structure are provided. A tissue structure is obtained by co-culturing an endodermal, ectodermal, or mesodermal cell derived from a stem cell and at least one cell and / or factor selected from the group consisting of a vascular cell, a mesenchymal cell, a factor secreted by a vascular cell, a factor secreted by a mesenchymal cell, and a factor secreted when both a vascular cell and a mesenchymal cell exist. A value obtained by assay of a plurality of functions using a Pearson product-moment correlation coefficient is closer to a value of a cell or biological tissue sampled from an adult than a value of a cell or biological tissue sampled from a fetus.

The present invention provides a method for inducing differentiation of pluripotent stem cells into mesodermal cells, comprising the step of culturing pluripotent stem cells in a serum-free medium without forming an embryoid body and without coculturing with cells from a different species.

A method for producing renal progenitor cells from pluripotent stem cells, comprising steps (i) to (vi): (i) culturing the pluripotent stem cells in a culture medium containing FGF2, BMP4, a GSK-3[beta] inhibitor and retinoic acid or a derivative thereof; (ii) culturing cells produced in step (i) in a culture medium containing FGF2, a GSK-3[beta] inhibitor and BMP7; (iii) culturing cells producedin step (ii) in a culture medium containing FGF2, a GSK-3[beta] inhibitor, BMP7 and a TGF[beta] inhibitor; (iv) culturing cells produced in step (iii) in a culture medium containing FGF2, a GSK-3[beta] inhibitor, BMP7, activin and a ROCK (Rho-kinase) inhibitor; (v) culturing cells produced in step (iv) in a culture medium containing retinoic acid or a derivative thereof and FGF9; and (vi) culturing cells produced in step (v) in a culture medium containing a GSK-3[beta] inhibitor and FGF9 to induce renal progenitor cells from intermediate mesodermal cells.

The invention provides a method of using multipotent stem cells to prepare epicardial cells, comprising: 1) inducing multipotent stem cells to differentiate into mesodermal cells by activating a WNT signal pathway; 2) converting the mesodermal cells in step 1) into myocardial precursor cells by inhibiting the WNT signal pathway; 3) converting the myocardial precursor cells in step 2) into preliminary epicardial cells by activating a fibroblast growth factor signal pathway and the WNT signal pathway; preparing pericardial cells with the preliminary epicardial cells of step 3). The invention also relates to: a method of using multipotent stem cells to prepare vascular smooth muscle cells and cardiac fibroblasts; epicardial cells, vascular smooth muscle cells and cardiac fibroblasts all of which are prepared through the above method; and their application.

This invention provides pertains to the discovery that that nicotine interrupts molecular signaling between endodermal and mesodermal cells of the lung alveolus. Treatment of the lung with specific molecular agents (e.g., PPAR gamma agonists) can prevent and / or reverse the injury caused by nicotine.

The present invention provides a method for inducing pluripotent stem cells to differentiate into ventricular myocytes in vitro, which is to maintain, amplify, and cultivate pluripotent stem cells in vitro, and in the middle stage of myocardial differentiation of pluripotent stem cells, the mesoderm cells or myocardial precursor cells develop into In the period of cardiomyocyte differentiation, substances that can directly or indirectly activate the Smad1 / 5 / 8 signaling pathway are added to the medium to make the stem cells differentiate into ventricular myocytes. Utilizing the method of the present invention, ventricular myocytes with biological activity and function have been successfully obtained, which not only reveals the regulatory mechanism in the differentiation process of myocardial precursor cells into ventricular myocytes, but also differentiates human ventricular myocytes to cell transplantation for the treatment of myocardium. Infarction and cardiac toxicology analysis and the development of cardiac-related drugs have a wide range of applications.

The invention discloses a pharmaceutical composition for treating female reproductive track infection and a preparation method thereof. The pharmaceutical composition comprises polylysine microspheres, fructus ligustri lucidi, radix sophorae flavescentis, fructus cnidii, Chinese usnea, poloxamer F127 and poloxamer F68, wherein the content of the polylysine microspheres is 0.01-0.05% by mass percent; the total content of fructus ligustri lucidi, radix sophorae flavescentis, fructus cnidii and Chinese usnea is 1-7%; the ratio of fructus ligustri lucidi to radix sophorae flavescentis to fructus cnidii to Chinese usnea is 1:1:2:1; the content of poloxamer F12 is 17-30%; the content of F68 is 0-20%; and the rest is water. After the polylysine microspheres and the traditional Chinese medicine composition are compounded, vaginal wound healing is effectively promoted. The pharmaceutical composition has a repair and regeneration promotion function on cells of a mesoderm and an ectoderm, and canpromote regeneration of blood capillaries, improve the local blood circulation and quicken wound healing. Polylysine becomes amino acid after being decomposed and can serve as a nutrient substance tobe absorbed.

This invention provides unique members of the Hect family of ubiquitin ligases that specifically target BMP and TGF beta / activin pathway-specific Smads. The novel ligases have been named Smurf1 and Smurf2. They directly interact with Smads1 and 5 and Smad7, respectively, and regulate the ubiquitination, turnover and activity of Smads and other proteins of these pathways. Smurf1 interferes with biological responses to BMP, but not activin signalling. In amphibian embryos Smurf1 inhibits endogenous BMP signals, resulting in altered pattern formation and cell fate specification in the mesoderm and ectoderm. The present invention provides a unique regulatory link between the ubiquitination pathway and the control of cell fate determination by the TGF beta superfamily during embryonic development. Thus, Smurf1 is a negative regulator of Smad1 signal transduction, by targeting Smad1, Smurf1 blocks BMP signalling. In mammalian cells, Smurf2 suppresses TGF beta signalling, and in Xenopus, blocks formation of dorsal mesoderm and causes anterior truncation of the embryos. Smurf2 forms a stable complex with Smad7, which induces degradation and downregulation of TGF beta / activin signalling.

The invention relates to a method for reprogramming target cells to multipotent progenitor cells capable of differentiating into muscular, skeletal or dermal cell lines. In particular, the invention relates to an ex vivo method for preparing induced presomitic mesoderm (iPSM) cells, said method comprising the steps of: a) providing target cells to be reprogrammed, and, b) culturing said target cells under appropriate conditions for reprogramming said target cells into iPSM cells, wherein said appropriate conditions comprises increasing expression of at least one T-Box transcription factor in said target cells. The invention further relates to the use of said iPSM cells, for example, for regenerating skeletal, muscle, dermal and cartilage tissues.

The present invention relates to a method of generating neural stem cells from mesodermal cells. The invention further provides a cell population which has neural stem cell-like characteristics. The neural stem cells prepared according to the invention are useful in the treatment of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

The invention relates to a method for inducing differentiation into NK cells from human embryonic stem cells, belonging to the technical field of genetic engineering; the method includes the recovery and passage of human embryonic stem cells, inducing mesodermal cells, and inducing CD34 cells + Hematopoietic stem cells, isolation and purification of CD34 + Hematopoietic stem cells, induced to obtain NK cells, expanded and cultured; the human embryonic stem cells are human embryonic stem cell line H9; the recovery and passage of the human embryonic stem cells, the human embryonic stem cells are revived and passaged, passed to the second generation, and the cells are confluent When the ratio is more than 80%, it is used to induce mesodermal cells; the present invention uses human embryonic stem cells to induce differentiation to obtain NK cells, and when the effect-target ratio is 20:1, the killing rate of HELA tumor cell line The killing rate of the LOVO tumor cell line was 91.24%.

The invention relates to a method for inducing directional endothelial differentiation of human pluripotent stem cells. The method specifically comprises the following steps: 1, when the human pluripotent stem cells reach 80% fusion or above, induced differentiation is performed on digested stem cells by using a differential medium containing 10-50ng / ml of WNT3a; 2, induced differentiation is further performed on the cells by using a differentiation medium containing 10-50ng / ml of WNT3a and 10-30ng / ml of BMP2; 3, induced differentiation is further performed on the induced differentiated cells in the step 2 by using a differential medium containing 10-30ng / ml of BMP2 into mesodermal cells; and 4, induced differentiation is further performed on the cells by using a culture medium containing 10-15ng / ml of FGF8 into endothelial cells. According to the invention, by improving the mediums and related cell factors, the experimental scheme can have higher endothelial induction efficiency.

The present invention provides a method of producing an osteoblast construct from human iPS cells, the method including the steps of: (1) inducing formation of an embryoid body by subjecting undifferentiated human iPS cells to non-adherent culture; (2) inducing differentiation of the human iPS cells into mesodermal cells by subjecting the embryoid body of the human iPS cells obtained in the step (1) to non-adherent culture; and (3) inducing differentiation into osteoblasts by subjecting the mesodermal cells of the human iPS cells obtained in the step (2) to non-adherent culture.

The present invention provides a method of producing an osteoblast construct from human iPS cells, the method including the steps of: (1) inducing formation of an embryoid body by subjecting undifferentiated human iPS cells to non-adherent culture; (2) inducing differentiation of the human iPS cells into mesodermal cells by subjecting the embryoid body of the human iPS cells obtained in the step (1) to non-adherent culture; and (3) inducing differentiation into osteoblasts by subjecting the mesodermal cells of the human iPS cells obtained in the step (2) to non-adherent culture.

An object of the present invention is to provide a method for differentiating mesodermal cells into mesothelium cells. The present invention provides a method for producing mesothelial cells, including a first culturing step of culturing mesodermal cells in a medium containing basic fibroblast growth factor (bFGF) and oncostatin M.

The present invention provides a method of inducing mesoderm derived cells from pluripotent stem cells. In contrast to methods known in the art that are often designed to replicate in vivo events of mesoderm induction, the present invention provides a unique, yet simple, method whereby pluripotent stem cells are mesodermally primed in the presence of factors that concomitantly inhibit the spontaneous differentiation of endoderm and ectoderm during expansion and suspension steps. Exposure and / or adherence of primed aggregates to a extracellular matrix that promotes the commitment and survival of induced mesoderm progenitors, followed by exposure to various mesoderm associated factors, allows for the subsequent induction of such cells into terminally differentiated lineages, such as cardiomyocytes. End products of this induction system will ultimately provide an unlimited source of mesoderm-derived cell types for therapeutic and pharmacological purposes.

There is provided a method for the simultaneous production of nephron progenitor cells and ureteric epithelial progenitor cells, comprising the step of contacting intermediate mesoderm cells with fibroblast growth factor 9 and / or fibroblast growth factor 20 , and optionally one or more selected from: bone morphogenetic protein 7; heparin; Wnt agonists; retinoic acid; The concentrations of Wnt agonist, retinoic acid and / or RA antagonist can be manipulated to favor the relative production of nephron progenitor cells and ureteric epithelial progenitor cells. The intermediate mesoderm cells are ultimately derived from human pluripotent stem cells via the posterior primitive streak stage. The nephron progenitor cells and ureteric epithelial progenitor cells may have end uses such as for kidney repair and regeneration, bioprinting of kidneys, and screening of compounds for nephrotoxicity.

The present disclosure provides a method for determining the undifferentiated state of a pluripotent stem cell, the method comprising irradiating a culture medium being tested in which the pluripotentstem cell is cultured, with light having wavelengths in all or a part of the range of 190-2500 nm, detecting reflected light, transmitted light, or transmitted and reflected light thereof to obtain absorbance spectral data, and analyzing the absorbances in all or in a partial range of the measured wavelengths of the absorbance spectral data, on the basis of an analysis model which is previously created using a plurality of types of control culture media used in culturing the pluripotent stem cell, to determine the undifferentiated state of the pluripotent stem cell, wherein the plurality of types of control culture media include one or more differentiation-inducing media selected from a medium used in maintaining the undifferentiated state of the pluripotent stem cell, a medium for inducing differentiation to an ectodermal cell, a medium for inducing differentiation to a mesodermal cell, and a medium for inducing differentiation to an endodermal cell.